Methylphenidate in Childhood Apraxia of Speech

Murdoch Childrens Research Institute

Status and phase: Enrolling; Phase 2

Conditions: Childhood Apraxia of Speech

Treatments: Drug: Methylphenidate Hydrochloride; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05185583

77169

Details and patient eligibility

About

The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.

Full description

This is a randomised, double-blind, placebo-controlled, two-period crossover proof-of-concept trial of methylphenidate (MPH) for children with childhood apraxia of speech (CAS). 24 children aged 6 to 12 years with CAS will be recruited. If children pass the screening procedure, which includes a physical exam conducted by a medical officer at the Melbourne Children's Campus, children will be enrolled into the 8 weeks + 2-day trial (includes 2-day washout). Participants will be randomly assigned to sequence A (4 weeks of MPH, followed by 4 weeks of placebo) or sequence B (4 weeks of placebo, followed by 4 weeks of MPH). After 4 weeks in period 1, a two-day washout period will occur before participants crossover to period 2 for 4 weeks. Pre- and post-treatment speech outcomes will be measured. The investigators' primary objective is to provide proof-of-concept that speech intelligibility could demonstrate greater improvements from baseline to 4 weeks following a 4-week period of MPH use compared with placebo in children with CAS. The secondary objectives are to describe feasibility, tolerability and change from baseline in: connected speech intelligibility, quality of language production, speech quality, functional speech intelligibility, phonological working memory, attentional and hyperactive behaviour.

Enrollment: 24 estimated patients

Sex: All

Ages: 6 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has childhood apraxia of speech
• Aged 6-12 years
• Can perform the speech tasks for the trial (able to speak single words and short sentences)
• English as a first language
• Has adequate hearing
• Has a legally acceptable representative capable of understanding the informed consent document and providing consent on their behalf
• Passes the health and medical examination including examination of heart rate and blood pressure for age and weight norms
• Can commit to the time requirements of the trial
• Lives within 250 kilometres of the study site (MCRI)
• Able to swallow a capsule
• Scores 13 or more out of 27 on either the inattention and/or hyperactivity subscales of the SNAP-IV Parent 18-Item Rating Scale, suggesting clinically significant symptoms of inattention and/or hyperactivity

Exclusion criteria

• Is unable to commit to the time requirements of the trial (8 weeks + 2 days)
• Has a diagnosis of severe intellectual disability, or other significant neurodevelopmental conditions (e.g., Fragile X, Down Syndrome, etc.)
• Has epilepsy or other seizure disorders
• Is taking medication(s) for another health condition(s) that is known to interfere with MPH
• Has any contraindication to the stimulant (methylphenidate) medication, including severe anxiety, depression, severe Tourette syndrome, glaucoma, psychotic symptoms, hypertension, congenital heart disease, known past or present diagnosed substance abuse or dependence
• Has a score of moderate or high risk of suicidality, assessed with the Columbia Suicidality Severity Rating Scale (C-SSRS)
• Has used psychostimulants within the past 3 months (e.g., Ritalin, Concerta, Focalin)
• Lives more than 250 kilometres from the study site
• Unable to swallow a capsule

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

24 participants in 2 patient groups

Sequence A: Methylphenidate, Placebo

Experimental group

Description:

Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.

Treatment:

Drug: Placebo

Drug: Methylphenidate Hydrochloride

Sequence B: Placebo, Methylphenidate

Experimental group

Description:

Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.

Treatment:

Drug: Placebo

Drug: Methylphenidate Hydrochloride